Changes in Hong Kong stocks | Yao Ming Kangde (02359) rose more than 4% to a new high. Preliminary ban application approved. The company fully raised its 2026 performance guidelines

The Zhitong Finance App learned that Yao Ming Kangde (02359) rose more than 4% in early trading, to a high of HK$207, another record high. As of press release, it rose 4.26% to HK$205.8, with a turnover of HK$903 million.

According to the news, on August 7, the US District Court for the District of Columbia approved Yao Ming Kant's preliminary injunction application, prohibiting the US Department of Defense from enforcing the effect of listing on the 1260H list during the litigation of this case. According to reports, this is the first phased victory for a Chinese biomedical company to challenge the US military list. It also provides a guarantee for Chinese CDMO companies to maintain customer and supply chain confidence in global pharmaceutical companies and to ensure the smooth delivery of new orders.

It is worth noting that Yao Ming Kangde comprehensively raised its 2026 annual results guide. Annual revenue was raised from 513-53 billion yuan to 585-60.5 billion yuan, and the continuous operating revenue growth rate increased sharply from 18%-22% to 35%-39%. At the same time, the company accelerated its global production capacity layout. Capital expenditure was raised from 65-7.5 billion yuan to 75-8.5 billion yuan, adjusted free cash flow was raised from 105-11.5 billion yuan to 135-14.5 billion yuan, and revenue, profit, and cash flow increased across the three levels.